Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.52
PACB's Cash to Debt is ranked lower than
63% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. PACB: 5.52 )
Ranked among companies with meaningful Cash to Debt only.
PACB' s 10-Year Cash to Debt Range
Min: 5.52  Med: 47.92 Max: No Debt
Current: 5.52
Equity to Asset 0.38
PACB's Equity to Asset is ranked lower than
79% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PACB: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
PACB' s 10-Year Equity to Asset Range
Min: -2.1  Med: 0.77 Max: 0.92
Current: 0.38
-2.1
0.92
F-Score: 4
Z-Score: -6.06
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -96.01
PACB's Operating margin (%) is ranked lower than
54% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. PACB: -96.01 )
Ranked among companies with meaningful Operating margin (%) only.
PACB' s 10-Year Operating margin (%) Range
Min: -65237.04  Med: -363.08 Max: -103.73
Current: -96.01
-65237.04
-103.73
Net-margin (%) -101.28
PACB's Net-margin (%) is ranked lower than
56% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. PACB: -101.28 )
Ranked among companies with meaningful Net-margin (%) only.
PACB' s 10-Year Net-margin (%) Range
Min: -64965.19  Med: -363.56 Max: -109.19
Current: -101.28
-64965.19
-109.19
ROE (%) -119.17
PACB's ROE (%) is ranked lower than
85% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. PACB: -119.17 )
Ranked among companies with meaningful ROE (%) only.
PACB' s 10-Year ROE (%) Range
Min: -272.85  Med: -88.81 Max: -46.42
Current: -119.17
-272.85
-46.42
ROA (%) -54.23
PACB's ROA (%) is ranked lower than
72% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. PACB: -54.23 )
Ranked among companies with meaningful ROA (%) only.
PACB' s 10-Year ROA (%) Range
Min: -81.89  Med: -56.97 Max: -41.75
Current: -54.23
-81.89
-41.75
ROC (Joel Greenblatt) (%) -879.48
PACB's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. PACB: -879.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PACB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2466.26  Med: -726.17 Max: -528.3
Current: -879.48
-2466.26
-528.3
Revenue Growth (3Y)(%) 10.90
PACB's Revenue Growth (3Y)(%) is ranked higher than
66% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PACB: 10.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PACB' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 15.60 Max: 38.3
Current: 10.9
0
38.3
EBITDA Growth (3Y)(%) -24.20
PACB's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. PACB: -24.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PACB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -67.60 Max: -24.2
Current: -24.2
EPS Growth (3Y)(%) -22.60
PACB's EPS Growth (3Y)(%) is ranked lower than
69% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. PACB: -22.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PACB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -66.95 Max: -22.6
Current: -22.6
» PACB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PACB Guru Trades in Q2 2014

Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

PACB Guru Trades in Q3 2014

Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
» More
Q4 2014

PACB Guru Trades in Q4 2014

Jim Simons 137,972 sh (New)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie 6,459,784 sh (unchged)
» More
Q1 2015

PACB Guru Trades in Q1 2015

Paul Tudor Jones 25,700 sh (New)
Lee Ainslie 7,061,034 sh (+9.31%)
Murray Stahl 12,000 sh (unchged)
Jim Simons 125,200 sh (-9.26%)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.54
PACB's P/B is ranked lower than
79% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. PACB: 10.54 )
Ranked among companies with meaningful P/B only.
PACB' s 10-Year P/B Range
Min: 0.52  Med: 2.69 Max: 11.43
Current: 10.54
0.52
11.43
P/S 6.18
PACB's P/S is ranked higher than
67% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. PACB: 6.18 )
Ranked among companies with meaningful P/S only.
PACB' s 10-Year P/S Range
Min: 2  Med: 7.54 Max: 28.19
Current: 6.18
2
28.19
Current Ratio 2.59
PACB's Current Ratio is ranked lower than
68% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. PACB: 2.59 )
Ranked among companies with meaningful Current Ratio only.
PACB' s 10-Year Current Ratio Range
Min: 2.59  Med: 8.69 Max: 14.06
Current: 2.59
2.59
14.06
Quick Ratio 2.24
PACB's Quick Ratio is ranked lower than
67% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. PACB: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
PACB' s 10-Year Quick Ratio Range
Min: 2.24  Med: 8.33 Max: 13.74
Current: 2.24
2.24
13.74
Days Inventory 98.56
PACB's Days Inventory is ranked higher than
59% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. PACB: 98.56 )
Ranked among companies with meaningful Days Inventory only.
PACB' s 10-Year Days Inventory Range
Min: 104.94  Med: 173.85 Max: 196.1
Current: 98.56
104.94
196.1
Days Sales Outstanding 28.98
PACB's Days Sales Outstanding is ranked higher than
79% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. PACB: 28.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
PACB' s 10-Year Days Sales Outstanding Range
Min: 20.52  Med: 35.57 Max: 74.35
Current: 28.98
20.52
74.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 31.61
PACB's Price/Net Cash is ranked lower than
85% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. PACB: 31.61 )
Ranked among companies with meaningful Price/Net Cash only.
PACB' s 10-Year Price/Net Cash Range
Min: 1.02  Med: 3.30 Max: 32.44
Current: 31.61
1.02
32.44
Price/Net Current Asset Value 12.65
PACB's Price/Net Current Asset Value is ranked lower than
68% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. PACB: 12.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PACB' s 10-Year Price/Net Current Asset Value Range
Min: 0.89  Med: 3.03 Max: 12.98
Current: 12.65
0.89
12.98
Price/Tangible Book 10.54
PACB's Price/Tangible Book is ranked lower than
72% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. PACB: 10.54 )
Ranked among companies with meaningful Price/Tangible Book only.
PACB' s 10-Year Price/Tangible Book Range
Min: 0.8  Med: 2.85 Max: 10.81
Current: 10.54
0.8
10.81
Price/Median PS Value 0.82
PACB's Price/Median PS Value is ranked higher than
71% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. PACB: 0.82 )
Ranked among companies with meaningful Price/Median PS Value only.
PACB' s 10-Year Price/Median PS Value Range
Min: 0.39  Med: 0.98 Max: 3.59
Current: 0.82
0.39
3.59
Earnings Yield (Greenblatt) (%) -18.80
PACB's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PACB: -18.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PACB' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 188.2  Med: 445.60 Max: 26942.4
Current: -18.8
188.2
26942.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:P09.Germany,
Pacific Biosciences of California Inc was incorporated in the State of Delaware in 2000. The Company develops, manufactures and markets an integrated platform for high resolution genetic analysis. It has developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, it created a technology platform using its proprietary single molecule, real-time, or SMRT, technology. Its SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events. The ability to observe single molecule events in real time provides the scientific community with a tool for investigating basic biochemical processes such as DNA synthesis. Its SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. It has commercialized the PacBioRS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, its products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations. The Company's products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS. Its competitors include Illumina Inc. and Thermo Fisher Scientific Inc. The names "Pacific Biosciences," "PacBio," "SMRT," "SMRTbell" and its logo are the trademarks of the Company. It is subject to federal, state, local and foreign laws, regulations and permits relating to environmental, health and safety matters.
» More Articles for PACB

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: CLR, CLMS, OPK, PACB, GAIN Dec 16 2013 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 
Weekly CEO Buys Highlight: PHII, TUES, PACB, IPHI, WMC Dec 09 2012 
Weekly CEO Buys Highlight: PACB, AKS, EPIQ, GGS, TPGI Dec 02 2012 
Weekly CEO Buys Highlight: FFIN, STEC, MPO, PACB, TPGI Nov 25 2012 
Weekly CEO Buys Highlight: SUNS, PACB, GM, NPO, DGX Aug 11 2012 

More From Other Websites
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Entry into a Material Definitive... Jul 24 2015
5 Stocks Poised for Breakouts Jul 24 2015
Pacific Biosciences of California, Inc. Second Quarter 2015 Financial Results Call Jul 13 2015
Pacific Biosciences of California, Inc. Second Quarter 2015 Financial Results Call Jul 13 2015
New Publications Highlight Utility of Single Molecule, Real-Time Sequencing for Structural Variation... Jul 13 2015
Pacific Biosciences (PACB) Jumps: Stock Moves 7.3% Higher - Tale of the Tape Jun 29 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Submission of Matters to a Vote of... May 22 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Financials May 13 2015
10-Q for Pacific Biosciences of California, Inc. May 07 2015
10-K for Pacific Biosciences of California, Inc. May 06 2015
Pacific Biosciences Posts Loss as Expected, '15 View Up - Analyst Blog May 06 2015
Pacific Biosciences Achieves Second Development Milestone in Clinical Diagnostics Agreement With... May 05 2015
Pacific Biosciences of California, Inc. Announces First Quarter 2015 Financial Results May 05 2015
7 Key After-Hours Movers on Tuesday May 05 2015
Pacific Biosciences reports 1Q loss May 05 2015
Pacific Biosciences reports 1Q loss May 05 2015
Pacific Biosciences of California Inc Earnings Call scheduled for 4:30 pm ET today May 05 2015
Pacific Biosciences and RainDance Technologies Partner to Co-Develop and Commercialize Novel... May 05 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Results of Operations and Financial... May 05 2015
Pacific Biosciences Achieves Second Development Milestone in Clinical Diagnostics Agreement With... May 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK